Dome and screw valves for remotely adjustable gastric banding systems

Information

  • Patent Grant
  • 8900118
  • Patent Number
    8,900,118
  • Date Filed
    Wednesday, May 15, 2013
    11 years ago
  • Date Issued
    Tuesday, December 2, 2014
    9 years ago
Abstract
An implantable device controls the movement of fluid to an inflatable portion of a gastric band. The implantable device includes a body. The body has an inlet, an outlet and a valve seat positioned between the inlet and the outlet. The body defines a fluid passage from the inlet to the outlet. The implantable device also includes a diaphragm. The diaphragm has one or more edges coupled to the body. The diaphragm is made of an elastomeric material and capable of being moved between a closed position that blocks the valve seat and does not allow the fluid to move from the inlet to the outlet and an open position that does not block the valve seat and allows the fluid to move from the inlet to the outlet.
Description
FIELD

The present invention generally relates to medical systems and apparatus and uses thereof for treating obesity and/or obesity-related diseases, and more specifically, relates to dome and screw valves for remotely adjustable gastric banding systems.


BACKGROUND

Adjustable gastric banding systems provide an effective and substantially less invasive alternative to gastric bypass surgery and other conventional surgical weight loss procedures. Despite the sustained weight loss of invasive weight loss procedures, such as gastric bypass surgery, it has been recognized that sustained weight loss can also be achieved through a laparoscopically-placed gastric band, for example, the LAP-BAND® (Allergan, Inc., Irvine, Calif.) gastric band or the LAP-BAND APO (Allergan, Inc., Irvine, Calif.) gastric band. Generally, gastric bands are placed about the cardia, or upper portion, of a patient's stomach forming a stoma that restricts the food's passage into a lower portion of the stomach. When the stoma is of an appropriate size that is restricted by a gastric band, food held in the upper portion of the stomach provides a feeling of satiety or fullness that discourages overeating. Unlike gastric bypass surgery procedures, adjustable gastric banding systems are reversible and require no permanent modification to the gastrointestinal tract.


Over time, a stoma created by the gastric band may need an adjustment in order to maintain an appropriate size, which is neither too restrictive nor too passive. Prior art gastric banding systems provide a subcutaneous fluid access port connected to an expandable or inflatable portion of the gastric band. By adding fluid to or removing fluid from the inflatable portion by means of a hypodermic needle inserted into the fluid access port, the effective size of the gastric band can be adjusted to provide a tighter or looser constriction.


It would be desirable to allow for non-invasive adjustment of gastric band constriction, for example, without the use of the hypodermic needle. Thus, remotely adjustable gastric banding systems capable of non-invasive adjustment are desired and described herein.


SUMMARY

In one example embodiment of the present invention, there is an implantable device that controls the movement of fluid to an inflatable portion of a gastric band. The implantable device includes a body. The body has an inlet, an outlet and a valve seat positioned between the inlet and the outlet. The body defines a fluid passage from the inlet to the outlet.


The implantable device also includes a diaphragm. The diaphragm has one or more edges coupled to the body. The diaphragm is made of an elastomeric material and capable of being moved between a closed position that blocks the valve seat and does not allow the fluid to move from the inlet to the outlet and an open position that does not block the valve seat and allows the fluid to move from the inlet to the outlet.


The implantable device also includes an actuator. The actuator is configured to apply a force on the diaphragm causing the diaphragm to move from the closed position to the open position. The implantable device also includes a microcontroller coupled to the actuator, the microcontroller configured to receive a telemetric signal from a remote transmitter and control the actuator based on the telemetric signal.


In another example embodiment of the present invention, there is an implantable device that controls the movement of fluid to an inflatable portion of a gastric band. The implantable device includes a body. The body has an inlet, an outlet and a valve seat. The body defines a fluid passage from the inlet to the outlet.


The implantable device also includes a valve seal. The valve seal has one or more edges coupled to the body. The valve seal is made of an elastomeric material and is capable of being moved between an open position that does not block the valve seat and allows the fluid to move from the inlet to the outlet and a closed position that blocks the valve seat and does not allow the fluid to move from the inlet to the outlet.


The implantable device also includes an actuator. The actuator is positioned within the body. The actuator has an actuator body defining a threaded screw hole and a screw positioned within the threaded screw hole. The screw is configured to apply a force on the valve seal causing the valve seal to move from the open position to the closed position when the actuator receives a telemetric signal from an implantable microcontroller. A first telemetric signal may be used to move the valve seal from the open position to the closed position and a second telemetric signal may be used to move the valve seal from the closed position to the open position.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a perspective view of a remotely adjustable gastric banding system according to an embodiment of the present invention.



FIG. 2 illustrates an example configuration of the internal components of the high precision pump unit illustrated in FIG. 1 according to an embodiment of the present invention.



FIGS. 3A and 3B illustrate the filling and draining, respectively, of a gastric band using the systems described herein according to an embodiment of the present invention.



FIGS. 4A and 4B illustrate cross-sectional views of an exemplary valve in a closed position and an open position according to an embodiment of the present invention.



FIGS. 5A and 5B illustrate cross-sectional views of an exemplary dome valve in a closed position and an open position according to an embodiment of the present invention.



FIGS. 6A and 6B illustrate cross-sectional views of an exemplary screw valve in a closed position and an open position according to an embodiment of the present invention.



FIGS. 7A, 7B and 7C illustrate side views of examples of the coupling mechanism illustrated in FIGS. 6A and 6B according to various embodiments of the present invention.



FIG. 8 is a flow chart of a method of controlling a dome valve according to an embodiment of the present invention.



FIG. 9 is a flow chart of a method of controlling a screw valve according to an embodiment of the present invention.





DETAILED DESCRIPTION

The present invention generally provides remotely adjustable gastric banding systems, for example, for treatment of obesity and obesity related conditions, as well as systems for controlling inflation of a gastric banding system.


Remotely adjustable gastric banding systems, otherwise referred to as a remotely adjustable band (RAB), include one or more medical devices, or a system, which allows a healthcare worker to adjust a gastric band without requiring a hypodermic needle to be inserted into an implanted access port. The RAB may use a remote transmitter to send radiofrequency signals or telemetric signals for powering and communicating with an implanted device of the RAB. The implanted device can fill or drain a gastric band of the RAB as requested by the healthcare worker via the remote transmitter. In between filling and draining adjustments to the gastric band, the volume of fluid contained in the gastric band ideally remains unchanged.


In one embodiment, a dome valve is used to pass and block fluid. The dome valve has an actuator that can adjust an elastomeric diaphragm (e.g., a valve seal) to an open or closed position. The dome valve can be used safely during magnetic resonance imaging (MRI) since the dome valve does not have a significant amount of ferromagnetic material. The elastomeric diaphragm is also inexpensive and robust.


In another embodiment, a screw valve is used to pass and block fluid. The screw valve has a screw that can adjust a valve seal to multiple precise positions, not just fully open or fully closed. The screw valve can be used in a high pressure environment since no force is required to maintain a position and because the screw can be driven to create a tight seal.



FIG. 1 illustrates a perspective view of a remotely adjustable gastric banding system 100 according to an embodiment of the present invention. The gastric banding system 100 includes a gastric band 102, a reservoir 104, a high precision pump unit 106, a remote transmitter 108 and tubing 110. The skin 122 of a human illustrates a separation between implantable components and non-implantable components. As illustrated, the remote transmitter 108 (e.g., a remote controller unit) is non-implantable, whereas the gastric band 102, the reservoir 104, the high precision pump unit 106, and the tubing 110 are implantable (e.g., an implantable device), and can be implanted in the human using conventional surgical techniques. The high precision pump unit 106 can be used to replace or complement a conventional access port for adjusting inflation or deflation of the gastric band 102. In some embodiments, the system includes an override port 212 which can be used, for example, with a hypodermic needle 112, to fill and drain the gastric band 102.


The high precision pump unit 106 is connected to the reservoir 104 and the gastric band 102 via the tubing 110, and can move precisely metered volumes of fluid (e.g., saline) in or out of the gastric band 102. Moving the fluid into the gastric band 102 causes inflation of at least one bladder, or an inflatable portion 114 (e.g., inflatable member) and constricts around the cardia, or upper portion of the stomach, forming a stoma that restricts the passage of food into a lower portion of the stomach. This stoma can provide a patient with a sensation of satiety or fullness that discourages overeating. In contrast, moving the fluid out of the inflatable portion 114 of the gastric band 102 reduces the pressure around the cardia and allows the stoma to be at least partially released and allows the human to regain a hunger sensation.


The high precision pump unit 106 is implanted within a patient, and therefore, is non-biodegradable. The encasement or housing of the high precision pump unit 106 may be non-hermetically sealed or hermetically sealed from the in situ environment (e.g., undisturbed environment) in the patient and formed at least partially of any rugged plastic material including, polypropylene, cyclicolephin co-polymer, nylon, and other compatible polymers and the like or at least partially formed of a non-radiopaque metal. The housing has a smooth exterior shape, with no jagged edges, to minimize foreign body response and tissue irritation. The high precision pump unit 106 is also sterilizable, in one embodiment, dry heat sterilizable before implantation.


The reservoir 104 may be a soft, collapsible balloon made of a biocompatible polymer material, for example, silicone, which holds a reserve of a biocompatible fluid, for example, saline, to allow for adjustments in the size of the gastric band 102. In one embodiment, the reservoir 104 is fully collapsible and can contain the extra fluid required to increase the volume of the gastric band 102 to therapeutic levels. Further, the reservoir 104 also may have excess capacity so the gastric band 102 may be fully drained into it without the reservoir 104 being filled beyond its maximum capacity.


The reservoir 104 may represent one or both of a source reservoir and a drain reservoir, where the source reservoir provides fluid to the gastric band 102, and the drain reservoir receives fluid from the gastric band 102.


The fluids used within the systems of the present invention may include any fluid that is biocompatible. The fluid has no adverse effect on the patient in the unlikely event that a leak emanates from the system. The fluid can simply be water or any biocompatible polymer oil such as castor oil. In an example embodiment, the fluid is saline.


The tubing 110 is any biocompatible flexible tubing that does not degrade in vivo (e.g., within the human). The tubing 110 is configured to withstand hydraulic pressure up to about 30 psi (about 206 kPa) without leakage. This hydraulic pressure tolerance is true of the entire fluid path of the systems described herein. Although the systems described herein do not generally leak, if they do, fluid is not lost at a rate greater than about 0.2 cc/yr, or about 0.1 cc/yr.


Other biocompatible and biostable polymers which are useful for forming the reservoir 104 and the tubing 110 include:


polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers, ethylene-co-vinylacetate, polybutylmethacrylate, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins, polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate, cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.


The systems and apparatus described herein further include the remote transmitter 108 (e.g., a remote controller unit), which provides access to system data and functions, and can be an external, handheld, reusable battery-powered device. The remote transmitter 108 can be made of any rugged plastic material including polypropylene, cyclicolephin co-polymer, nylon, and other compatible polymers and the like. The remote transmitter 108 is not implanted within the patient so hermetic sealing of the unit is not required. However, in one embodiment, the remote transmitter 108 is at least water resistant, if not waterproof, and can be cleaned using standard hospital disinfectants without damage to the unit.


Further, the remote transmitter 108 has a user interface including at least one display 116 and at least one user input 118. In some example embodiments, the display 116 and the user input 118 are combined in the form of a touch screen with a color display. In other embodiments, the display is grayscale. The remote transmitter 108 permits a clinician or a medical technician to navigate through menu driven screens used for data entry, data collection, and controlling the high precision pump unit 106.


The remote transmitter 108 is capable of communicating with the high precision pump unit 106. “Capable of communicating” as used herein refers to the remote controller's ability to establish communications with the high precision pump unit 106 yet still have the ability to break communication and the systems described herein still function. To establish communication, in one example embodiment, once the remote transmitter 108 is initialized, the display 116 shows a searching query for a nearby high precision pump unit 106. As the remote transmitter 108 is brought into range of the high precision pump unit 106, a symbol displays the strength of the communication link. Once stable communications have been acquired, the display 116 shows the serial number of the system so a clinician can verify they have the appropriate patient records in hand. If the patient requires a tightening of the gastric band 102, the clinician can enter the amount of the desired volume increase. The remote transmitter 108 can also display the current volume within the gastric band 102 and indicate the new volume as the gastric band 102 fills. The display 116 can also indicate desired and actual volumes during draining of the gastric band 102.


To verify the appropriate adjustment has been made to the system, the clinician can set the remote transmitter 108 into a pressure monitor mode and request that the patient drink water. The display 116 shows a real time graph of the pressure measured within the gastric band 102. This diagnostic tool may show higher pressures and warning messages if the gastric band 102 has been over-tightened.


The remote transmitter 108 can synchronize and charge when coupled with a charging cradle or docking station. This docking station provides the ability to recharge a rechargeable battery of the remote transmitter 108 and provides a link to download information to a personal computer such as the adjustment history of a patient. Other data that can be stored on the remote transmitter 108 and downloaded from the high precision pump unit 106 includes, but is not limited to serial number, gastric band size, patient information, firmware version and patient adjustment history. This data can be downloaded directly to a patient tracking database for easy tracking.


Any data stored on the remote transmitter 108 or within the high precision pump unit 106 can be electronically secured. In other words, security measures can be put in place to keep the data confidential, including communication between the high precision pump unit 106 and the remote transmitter 108. Security measures can include computer generated algorithms that prevent intrusion by outside parties.


The high precision pump unit 106 can contain a micro-fluidic pump with active valves. In such an embodiment, the high precision pump unit 106 is a passive device that can only be powered by the remote transmitter 108 when it is in close proximity. For example, in one example embodiment, the remote transmitter 108 may be configured to power and communicate with the high precision pump unit 106 at any distance less than about 8 inches, in one embodiment less than about 4 inches (about 10.2 cm) of tissue plus about 4 inches of air, and in another embodiment about 2 inches (about 5.1 cm) of air. Power and communications can be tailored to transmit over longer distances or can be tailored to have the remote transmitter 108 placed on the skin adjacent to the high precision pump unit 106.


Further, the remote transmitter 108 can provide an inductive power and telemetric control through a transmission 124 to the high precision pump unit 106. The remote transmitter 108 may be configured to provide continuous power to the high precision pump unit 106. A dedicated microcontroller within the remote transmitter 108 monitors the amount of power that is transmitted. Further still, a power management system may be implemented to optimize energy transmission between the remote transmitter 108 and the high precision pump unit 106 relative to their separation distance. For example, the power transmission may automatically decrease as the remote transmitter 108 is closer to the high precision pump unit 106, and may be increased as the distance is increased. This minimizes wasted energy, and energy exposure to the patient.


The systems and apparatus described herein use common surgical techniques to place the components in their respective positions within a patient. The surgical techniques may be identical or similar to those used in the placement of conventional gastric banding systems. For example, the gastric band 102 may be placed around the stomach using laparoscopic techniques, as known to those of skill in the art. Like a conventional access port, the high precision pump unit 106 may be sutured onto the rectus muscle sheath or any other conveniently accessible muscle. In order to achieve a secure attachment of the high precision pump unit 106, the unit shall be sutured to the rectus muscle and remain securely attached for forces below about 6 lbf, in one embodiment below about 3 lbf (13.3 N). The tubing 110 from the high precision pump unit 106 passes through the rectus muscle into the peritoneal cavity in the same manner as the tubing of a conventional access port.


The systems and apparatus of the present invention further allow for a remotely controlled adjustment without needles, non-invasively, by using the remote transmitter 108. Also, should the remote transmitter 108 be unavailable, damaged, out of power, or in the event of an emergency, an adjustment of the gastric band 102 can be performed invasively using a needle. By using the override port 212, a clinician can choose to use the hypodermic needle 112, a standard needle, or a syringe for adjustments. If any of the electronics associated with the systems and apparatus described herein become inoperable, the override port 212 can be used to add or remove fluid from the gastric band 102. The override port 212 and the hypodermic needle 112 can always be used to adjust the gastric band 102.



FIG. 2 illustrates an example configuration of the internal components of the high precision pump unit 106 illustrated in FIG. 1 according to an embodiment of the present invention. The housing of the high precision pump unit 106 has an internal volume of between about 0.75 in3 to about 1.6 in3. Exemplary internal features of the high precision pump unit 106 that fit within the housing include a first valve 202, a second valve 204, a pump 206, a pressure/flow sensor 208, an electronics board 210 including an antenna 211, and the override port 212. The internal components of the high precision pump unit 106 can be arranged in any fashion appropriate for delivering and removing precise amounts of fluid from the gastric band 102 and the reservoir 104.


The pump 206 can be actively or passively driven. If the pump 206 is actively driven, a local power source such as a battery (not illustrated) is provided to drive the pump 206. If the pump 206 is passively driven, it may be inductively powered by a device external to the high precision pump unit 106. In an exemplary configuration, the pump 206 is passively driven through inductive power from the remote transmitter 108.


In one example embodiment, the pump 206 is an inductively powered, electrically driven, positive displacement piezoelectric pump. The pump 206 provides a means to move fluid into the gastric band 102.


The pump 206 can move fluid from the reservoir 104 to the gastric band 102 at rates higher than about 0.5 cc/min, for example, higher than about 1 cc/min for band pressures less than about 20 psi (about 138 kPa) relative to the reservoir pressure. Alternatively, fluid can be drained from the gastric band 102 to the reservoir 104 at rates higher than about 0.5 cc/min, for example, higher than about 1 cc/min for band pressures above about 0.2 psi (about 1.38 kPa).


The first valve 202 and the second valve 204, illustrated in FIG. 2, can be any valve known in the art to allow precise delivery of fluid and precise flow rates therethrough. In one embodiment, the first valve 202 and the second valve 204 only allow fluid to move in one direction, therefore, the two valves are situated in parallel with the high precision pump unit 106 allowing fluid to drain back from the gastric band 102. Further, the first valve 202 and the second valve 204 should have a precision orifice that restricts the flow rate to a well-characterized, precise amount.


The gastric banding system 100 may further comprise at least one flow or pressure sensor 208 disposed, for example, within or adjacent to the high precision pump unit 106. In an exemplary embodiment, two pressure sensors are situated within the fluid pathway between the first valve 202 and the second valve 204 and the gastric band 102. During a no-flow condition, both of the pressure sensors may be used to measure pressure thereby providing the benefits of redundancy and averaging.


For example, sensing or measuring the pressure within the fluid pathway of the gastric banding system 100 provides diagnostic uses. A clinician can measure pressure while a patient drinks water, recording and analyzing resulting pressure fluctuations which can help determine if the gastric band 102 is too restrictive. Whether the gastric band 102 is too restrictive can also be confirmed by the patient's response (generally discomfort) upon drinking the water, and can then be appropriately adjusted. Further, sensing or measuring pressure in the gastric banding system 100 can be useful in diagnosing system leaks or obstructions. For example, if the pressure consistently drops over an extended period of time, the clinician can diagnose a leak within the system and plan for an appropriate treatment to fix the problem. In contrast, if there is an obstruction within the system with a sustained pressure rise over time, the clinician can diagnose an obstruction within the system and plan for an appropriate treatment to fix the problem.


The override port 212, as illustrated in FIGS. 1 and 2, is an optional feature of some of the embodiments of the present invention. The override port 212 can be manufactured from a metal or a non-radiopaque material and is accessible by insertion of the hypodermic needle 112 (in FIG. 1) through a self-sealing septum 214 (in FIG. 2). The override port 212 allows a clinician to use the hypodermic needle 112 or a standard syringe to fill or drain the gastric band 102. Further, the override port 212 may be located on the distal end 216 of the high precision pump unit 106, for example, at a position substantially opposite from the proximal end 218 where the tubing 220 extends from the high precision pump unit 106. This placement of the override port 212 thereby reduces possible occurrences of a needle damaging the tubing 220. An extension body 222 emanating from the high precision pump unit 106 further protects the tubing 220 from accidental needle sticks.


The high precision pump unit 106 can be a passive device which may be entirely controlled and powered by the remote transmitter 108. The antenna 211 on the electronics board 210 is housed within the high precision pump unit 106 and the remote transmitter 108 is coupled to allow the transmission 124 of signals and power through the skin 122 (as illustrated in FIG. 1). The power issued from the remote transmitter 108 is continually monitored by a dedicated microprocessor to ensure that power transmission is minimized to the lowest level required for operation. To minimize the transmission 124 of power and to optimize the transmission 124 of command communication, the high precision pump unit 106 and the remote transmitter 108 have a channel frequency dedicated to command communication and a separate channel frequency dedicated to power transmission. The command communication can be configured, for example, to take place at about 402-406 MHz while the power transmission, for example, takes place at about 400 kHz. This command communication adheres to the frequency and power standards set by the Medical Implant Communications Service. To ensure accuracy, communication and control commands are verified by error check algorithms prior to data reporting or command implementation.


A portion of the electronics board 210 within the high precision pump unit 106 is devoted to conditioning and managing the power received at the antenna 211 or from a local battery. Communication electronics manage the bidirectional transmissions with timing verification and error checking. Controller circuits of the electronics board 210 send commands to the first valve 202, the second valve 204, the pump 206, and the pressure/flow sensor 208 and receive data back from the pressure/flow sensor 208. The electronics board 210 can be encased in a biocompatible sealant if further protection, or redundant protection, is necessary.


In one example embodiment, the systems and apparatus described herein are configured and structured to be compatible with MRI, or MRI safe, at, for example 1.5 T. In the exemplary embodiment shown, the high precision pump unit 106 is entirely inductively powered. The systems utilize no permanent magnets, no long metallic wires or leads, and a minimal or negligible amount of ferrous or ferromagnetic material. The systems are substantially free or contain substantially no ferromagnetic materials. Substantially no ferromagnetic materials refers to materials containing less than about 5%, in one embodiment, less than about 1% or 0.1% (w/w) of ferromagnetic material. The resulting systems are thus MRI safe given standard specifications regulating translational and rotational attraction, MRI heating, and imaging artifacts. In one embodiment, all materials selected for the systems are selected to be compatible and safe in an MRI environment.


Further, the inductive powering of the high precision pump unit 106 requires that energy be passed through body tissue. Since the body tissue absorbs a small amount of the energy passing through it, the heating of the tissue can be proportional to the total energy transferred. To ensure that the systems meet standards to minimize tissue heating (below 2° C. above body temperature per ISO 45652), the systems described herein have been designed to use very little power to move the fluid within the system and do not cause excessive heating of the patient's tissue.


The pressure/flow sensor 208 can monitor pressure inside the gastric band 102 as needed. Using the remote transmitter 108 to communicate with the high precision pump unit 106, a clinician can monitor pressure inside the gastric band 102, for example, in “real time” during an adjustment of the constriction within the gastric band 102. This will allow the clinician to observe the response of the gastric band 102 to a patient's adjustment. This may permit a new modality for the gastric band 102 adjustment management to monitor pressure as well as volume during an adjustment. With these new pressure sensing capabilities, the clinician can make a determination of whether there is a leak within the system (e.g., zero pressure reading) or whether there is an obstruction in the system (e.g., prolonged pressure rise).


In an example embodiment, the high precision pump unit 106 includes a first fluid line including a first pump for passing fluid in a first direction and a second fluid line in parallel with the first fluid line including a first valve and a second pump for passing fluid in an opposing direction. In another example embodiment, the second pump is not needed because the gastric band 102 provides enough pressure to move the fluid to the reservoir 104. The parallel line configuration allows for filling and draining of the gastric band 102 with a minimal number of components and minimal complexity.


The systems and apparatus described herein can achieve at least one of the following features. The total time required to complete a fill or drain of the gastric band 102 does not exceed about 10 minutes, and in one embodiment, about 5 minutes. The systems are able to adjust the volume in the gastric band 102 accurately to within about 0.1 cc or about 10%, whichever is greater. The pressure/flow sensor 208 has a resolution between about 0.010 psi to about 0.025 psi, and in one embodiment, about 0.019 psi (about 130 Pa).


In one example embodiment of the present invention, components of the systems can be replaced without replacing the entire system and subjecting patients to overly invasive surgeries to replace entire systems when a single component is defective or damaged. For example, if the high precision pump unit 106 becomes damaged, it can be replaced independently of other components. Alternatively, if the gastric band 102 becomes damaged, it can be replaced independently of other components. The same is true of the tubing 110 and the reservoir 104. Although components can be disconnected for single part replacement, components shall not become dislodged from the tubing 110 for tubing pull-off forces less than about 10 lbf, and in one embodiment, less than about 5 lbf (22.2 N).


The systems described herein meet at least one safety specification. For example, in the event of any failure of the systems, either no change in the gastric band 102 tightness or a loosening of the gastric band 102 results. Further, the high precision pump unit 106 is biocompatible for long term implantation and the remote transmitter 108 is biocompatible for transient use both per ISO 10993. The systems are designed to have no significant interaction or interference with other electronics in any of the following modalities: implantable energy sources such as defibrillators and pacemakers; internal energy sources such as electrosurgical instruments; external energy sources such as ultrasound, x-rays and defibrillators; and radiofrequency signals such as pacemaker programmers and neurostimulators.


Example 1
Implantation of a Gastric Band System

A 40 year old female is diagnosed by her clinician as obese, weighing 510 lbs. The clinician suggests to the patient that she consider the gastric banding system 100 according to the present invention. She agrees and undergoes the implantation procedure. The gastric band 102 is implanted around her cardia thereby creating a stoma. The high precision pump unit 106 is sutured onto the rectus muscle sheath and the tubing 110 and the reservoir 104 passes through the rectus muscle into the peritoneal cavity and connects to the gastric band 102. The gastric banding system 100 comes pre-filled, so there is no need for the clinician to fill the gastric banding system 100 during the surgical procedure. The patient is sutured and sent to recovery.


Example 2
Adjustment of a Gastric Band System

The female patient of Example 1, after the completion of the surgical implantation, has her gastric band system 100 properly adjusted by her clinician. The clinician holds the remote transmitter 108 to the skin 122 adjacent to the rectus muscle where the high precision pump unit 106 is located and initiates communication between the devices. An initial pressure of zero is displayed for the gastric band 102 as no fluid has been added to the gastric band 102. The clinician begins to fill the gastric band 102 using saline housed within the reservoir 104 at a rate of about 1 cc/min and the entire filling takes less than about 5 minutes.


After filling, to about 10 psi, the patient is instructed to drink a glass of water in order to properly assess the proper inflation pressure of the gastric band 102 to ensure it has not been over inflated. Upon confirmation that the gastric band 102 is properly inflated, the procedure is completed and the patient returns to her normal life.


The patient instantly notices that she is much less hungry than she previously had been and is consistently consuming less food as her appetite has been decreased. She returns to her clinician's office for a follow-up visit three months after her implantation and initial gastric band filling and she has lost 20 pounds. A year later, she has lost nearly 60 lbs.


The gastric banding system 100 generally functions as follows. When a clinician uses the remote transmitter 108 to adjust the gastric band 102, the high precision pump unit 106 initiates a sequence of events to move a precise amount of fluid in the desired direction, where the filling is discussed in FIG. 3A and the draining is discussed in FIG. 3B.



FIG. 3A illustrates the filling of the gastric band 102 according to an embodiment of the present invention. Just before pumping is initiated, the second valve 204, in line with the pump 206, is opened. The pump 206 creates a differential pressure to draw fluid out of the reservoir 104 and into the gastric band 102. The first valve 202 and the pressure/flow sensor 208 are closed or not engaged. The reservoir 104 is collapsible and does not impede the outward flow of fluid. Further, the reservoir 104 is sized such that when filled to the maximum recommended fill volume, there is a slight vacuum therein. Once the proper amount of fluid has been transferred from the reservoir 104 to the gastric band 102, the electronics board 210 (or circuitry thereon) shuts off the pump 206 and closes the second valve 204. The gastric band 102 now assumes the new higher pressure and fluid.


Referring to FIG. 3B, if the clinician decides that there is a need to loosen the gastric band 102, fluid is released from the gastric band 102 and returned to the reservoir 104. Once the high precision pump unit 106 receives a drain command from the remote transmitter 108, the first valve 202 behind the pressure/flow sensor 208 opens. The fluid is transferred from the gastric band 102 through the pressure/flow sensor 208 and the first valve 202 and into the reservoir 104. The amount of fluid released from the gastric band 102 can be monitored and determined by the pressure/flow sensor 208. Once the correct volume of fluid has been transferred, the first valve 202 is closed. With both the first valve 202 and the second valve 204 closed, the volume in the gastric band 102 is maintained and the pressure in the gastric band 102 can be measured accurately using the pressure/flow sensor 208.


When compared to conventional gastric banding systems having standard access ports which exclusively require syringe access (as opposed to being optional), the presently described systems and apparatus offer several benefits. First, the conventional access ports are located under a thick layer of fatty tissue, which is generally the case as the devices are generally used to treat obesity, and the access port can be difficult to locate. The present systems reduce or eliminate the need for (or to locate) the access port, as the use of the remote transmitter 108 removes the need for adjustment using the hypodermic needle 112.


Secondly, when accessing the access port in conventional systems, the ambiguity on its location may lead to damage by accidentally puncturing the tubing 110 which connects the access port 212 to the gastric band 102. This can require a revision surgery in order to repair the punctured tubing 110. Further, when a conventional access port cannot be located by palpation, x-ray imaging may be required to guide a needle into the access port. Such imaging practices put a patient at risk for x-ray radiation exposure. The present systems and apparatus remove the need for these unnecessary procedures and save the patient from x-ray radiation exposure. The present systems and apparatus are compatible with magnetic resonance imaging (MRI), which is much safer for a patient.


In the unlikely event that the override port 212 of the present invention needs to be used, the override port 212 may be located away from the tubing connection to the gastric band 102 to reduce the potential for tubing needle sticks. The high precision pump unit 106 has geometry and a rigid case that can be structured to facilitate the user in locating the override port 212 when needed.



FIGS. 4A and 4B illustrate cross-sectional views of an exemplary valve 400 in a closed position (FIG. 4A) and an open position (FIG. 4B) according to an embodiment of the present invention. The valve 400 may be used in place of one or both of the first valve 202 and the second valve 204.


Referring to FIG. 4A, the valve 400 is biased in a closed position, for example, by a spring preload force 402 acting on a seal 404, for example, a flexible silicone seal 404. For example, the spring preload force 402 pushes the flexible silicone seal 404 into sealing engagement with a valve seat 406. When the valve 400 is sealed as shown in FIG. 4A, fluid cannot pass from a valve inlet 408 to a valve outlet 410.


Now referring to FIG. 4B, when fluid flow is desired, a signal is sent to a valve actuator (not shown), which removes the spring preload force 402 and permits the flexible silicone seal 404 to relax or move upward into an open position, out of sealing engagement with the valve seat 406. The fluid is then free to flow from the valve inlet 408 to the valve outlet 410 until the valve 400 is closed, for example, by reapplication of the spring preload force 402.



FIGS. 5A and 5B illustrate cross-sectional views of an exemplary dome valve 500 in a closed position (FIG. 5A) and an open position (FIG. 5B) according to an embodiment of the invention. In one embodiment, the dome valve 500 is an implantable device that controls the movement of fluid to the inflatable portion 114 of the gastric band 102. The dome valve 500 may be used in place of one or both of first valve 202 and the second valve 204.


The dome valve 500 is designed to be implanted into a patient, and thus may be referred to as a micro valve. In an embodiment, the dome valve 500 has a length of about 15 mm (e.g., 10-25 mm range) and an about 10 mm outer diameter (e.g., 7-15 mm range). In one embodiment, the dome valve 500 is a radially symmetric shape (e.g., disk, tube, rod, etc.). However, the dome valve 500 can be any shape (e.g., circular, square, rectangular, etc). The dome valve 500 can include a body 560, an actuator 505, a cap 510, and a diaphragm 520.


The body 560 has an inlet component 530, an outlet component 535, and a bottom component 550. The inlet component 530, the outlet component 535, and the bottom component 550 have been identified for illustrative purposes and may not be separate components from the body 560. An inlet 540, which is a fluid entrance into the body 560, is defined between the inlet component 530 and the bottom component 550. An outlet 545, which is a fluid exit from the body 560, is defined between the outlet component 535 and the bottom component 550.


The inlet component 530 and the bottom component 550 form a valve seat 570. The valve seat 570 can be the surfaces (e.g., the tips) of the inlet component 530 and the bottom component 550 which provide sealing when the diaphragm 520 is placed against and in contact with the inlet component 530 and the bottom component 550. In one embodiment, the vertical column of the inlet component 530 and the bottom component 550 define the valve seat 570. The vertical columns may be short segments (e.g., 1.5 mm) of plastic or metal tubing (e.g., stainless steel).


The actuator 505 is configured to apply a force (e.g., stress) on the cap 510 causing the diagraph 520 to move from the closed position (FIG. 5A) to the open position (FIG. 5B) when the actuator 505 receives a telemetric signal 124 (e.g., electrical energy) from the remote transmitter 108. The force includes a smaller downward force 555 to keep the valve 500 in a closed position (FIG. 5A) and a larger downward force 565 to keep the valve 500 in an open position (FIG. 5B). In an embodiment, the smaller force 555 is less than 10 newtons. In an embodiment, the larger force 565 is between 10-100 newtons. In another embodiment, the larger force 565 is between 15-45 newtons.



FIG. 5A illustrates the actuator 505 applying the smaller force 555 (e.g., 0 newtons, little or no downward force, a reduced in force, a de-energized state), which is low enough to keep the valve 500 in the closed position. In particular, when the actuator 505 applies the smaller force 555, the cap 510 receives little or no downward force on cap edges 515. Since the cap edges 515 are adjacent to the diaphragm edges 525, the diaphragm edges 525 also receive little or no downward force. As such, the diaphragm center 527 of the diaphragm 520 remains sitting on (or relaxed onto) the valve seat 570, blocking fluid from flowing from the inlet 540 to the outlet 545.



FIG. 5B illustrates the actuator 505 applying a large force 565 (e.g., an energized state) that compresses (e.g., squeezes) the diaphragm edges 525 between the cap 510 and the body 560. The large force 565 is great enough that the material on the diaphragm edges 525 is compressed, with the cap 510 blocking diaphragm edges 525 from expanding outward, the diaphragm is expanded inward such that the diaphragm center 527 is moved up off the valve seat 570 due to a build-up of material. This opens a passage from the inlet 540 to the outlet 545 and permitting fluid flow in the valve 500 as shown by fluid flow indicators 575. When a downward force is applied, the diaphragm center 527 moves in a substantially opposite direction to the downward force.


The actuator 505 can take many forms (e.g., solenoids, stepper motors, piezoelectric actuator, electroactive polymer, etc.) as dictated by the specific application. In one embodiment of the RAB, the actuator 505 is a piezoelectric actuator. In another embodiment, the actuator 505 is an electroactive polymer.


The cap 510 may be positioned between the diaphragm 520 and the actuator 505. The cap 510 has one or more cap edges 515 (e.g., cap ends). The cap edges 515 direct the small force 555 and the large force 565 from the actuator 505 to the diaphragm 520. In one embodiment, the cap 510 is part of the actuator 505.


The diaphragm 520, which may be referred to as a valve seal, is positioned between the cap 510 and the body 560. The diaphragm 520 has a diaphragm center 527 (e.g., a body) and one or more diaphragm edges 525 (e.g., ends of the diaphragm 520) coupled to the body 560.


The diaphragm 520 (e.g., valve seal) has an open position (FIG. 5B) and a closed position (FIG. 5A). When the diaphragm 520 is in the open position, the diaphragm 520 does not block the valve seat 570 and therefore allows the fluid to move from the inlet 540 to the outlet 545. Conversely, when the diaphragm 520 is in a closed position, the diaphragm 520 blocks the valve seat 570 and does not allow the fluid to move from the inlet 540 to the outlet 545.


In one embodiment, the diaphragm 520 is made of an elastomeric material. The elastomeric material includes silicon and any other material that is stretchy like a rubber band. For example, the elastomeric material includes flexible materials, naturally occurring elastic substances (e.g., natural rubber), and synthetically produced substances (e.g., silicon, butyl rubber, neoprene).


The elastomeric material can be stretched across the valve seat 570 to provide a seal and can buckle to create a gap 526 above the valve seat 570. In an embodiment, the gap 526 below the diaphragm 520 is substantially less than 1 mm off the valve seat 570. In one embodiment, the gap 526 is about 0.03 mm. In one embodiment, the range for the gap 526 is between about 0.01 mm to about 0.25 mm. In another embodiment, the range for the gap 526 is between about 0.01 mm to about 0.10 mm.


In one embodiment, the diaphragm 520 is circular, although any shape is possible (e.g., a thin strip, rectangular, etc).


The dome valve 500 has numerous advantages over conventional valves. The dome valve 500 contains no ferromagnetic material as is commonly used in conventional valves (e.g., solenoid valves). As a result, the dome valve 500 advantageously can be safely used in conjunction with magnetic resonance imaging (MRI) scanning.


Additionally, the dome valve 500 advantageously is not concentric with the diaphragm, unlike conventional valves which have a concentric shaped seal which results in high susceptibility to leakage and contamination to the moving parts of the valve.


Advantageously, both the diaphragm 520 and the cap 510 restrict fluid from contacting the moving valve components, such as the actuator 505. This allows the dome valve 500 to be used in a system where the fluid is highly corrosive to the moving parts and can be used where the moving parts rub and create contaminants that must be keep free from the fluid, because the dome valve 500 protects the moving valve components from contamination.


Dome valve 500 advantageously can be inexpensively manufactured, due partly to the mechanical linkage, while still being robust and efficient. Opening the valve 500 requires very little stroke or travel from the actuator 505 to produce a suitably large upward deflection in the diaphragm 520. In contrast, conventional valves use energy inefficient methods such as forming a seal for a valve by heating a membrane comprised of two materials with different coefficients of linear thermal expansion.


Also, the dome valve 500 achieves a low leak/leakage rate when in the closed position (e.g., closed/sealed tightly) compared to conventional valves and achieves a high flow rate when in the open position. Further, the dome valve 500 minimizes the space required for the implanted device because the dome valve 500 can be smaller than other implantable devices.



FIGS. 6A and 6B illustrate cross-sectional views of an exemplary screw valve 600 in a closed position (FIG. 6A) and an open position (FIG. 6B) according to an embodiment of the present invention. The screw valve 600 is part of the RAB and may be used in place of one or both of the first valve 202 and the second valve 204. The screw valve 600 is designed small enough to be implanted into a patient, and thus may be referred to as a micro valve. In an embodiment, the screw valve 600 has a length of approximately 30-50 mm and an about 10 mm outer diameter (e.g., 7-15 mm range). In comparison to the dome valve 500 embodiment discussed above (10-25 mm length, 10 mm outer diameter), the screw valve 600 is almost twice as long, but has the same outer diameter.


The screw valve 600 in accordance with one embodiment of the present invention generally includes a body 660, a screw 615, a screw actuator 605, a coupling mechanism 610, a valve seal 620, and a valve seat 670.


The body 660 houses the components of the screw valve 600. The body 660 also has an inlet 640 and an outlet 645. The inlet 640 may be in communication with the reservoir 104 and the outlet 645 may be in communication with the inflatable portion 114 of the gastric band 102, or vice-versa, using suitable fluid port connectors, not shown.


The screw 615 includes a lead screw (where lead means a type of screw, and does not mean the material lead as used in a graphite pencil), power screw, translation screw. The screw 615 can be designed to translate radial (e.g., circular) motion/movement into linear (e.g., translational) motion/movement. The screw 615 is configured to apply a force on the valve seal 620 to cause the valve seal 620 to move from an open position (FIG. 6B) to a closed position (FIG. 6A) when the screw actuator 605 receives a telemetric signal 124 from the remote transmitter 108.


The screw actuator 605, positioned within the body 660 of the screw valve 600, has an actuator body defining a threaded screw hole 606. The screw 615 is positioned within the threaded screw hole 606.


In one embodiment, the screw actuator 605 is a motor. In another embodiment, the motor may be positioned within the screw actuator 605. In another embodiment, the motor is external to the body 660 for moving the screw 615.


The motor (not shown) may also be included in the screw valve 600 and coupled to the screw 615 for moving the screw 615 within the threaded screw hole 606. The motor can be a DC motor, an AC motor, a solenoid, a stepper motor, a piezoelectric actuator, a piezoelectric driver, and an electroactive polymer. In one embodiment, the motor is selected to be the same type of motor used elsewhere in the implantable system. The motor can be configured to move the screw 615 to at least two positions so that the valve seal 620 can be moved to at least two positions depending on the telemetric signal 124 sent from the remote transmitter 108 to the actuator 605.


The coupling mechanism 610, positioned between the valve seal 620 and the screw 615, decouples a rotational motion of the screw 615. In one embodiment, the coupling mechanism 610 may be securely fastened or fixed to the valve seal 620 so that the coupling mechanism 610 does not rotate with the rotation of the screw 615. The screw 615 moves forward and backward (or upward and downward) through both rotational and translational motion. However, to prevent damage to the valve seal 620, the valve seal 620 should only receive translational motion (not rotational motion). The coupling mechanism 610 decouples the rotational motion of the screw 615 but transmits the translational motion. The coupling mechanism 610 is illustrated as being a tappet, but can also include a ball bearing, a bellows unit, etc., as illustrated in FIGS. 7A-7C.


The valve seal 620 has one or more edges 621 coupled to the body 660. The valve seal 620 is capable of being moved from an open position that is spaced apart from the valve seat 670 and does not block a fluid (e.g., saline) from flowing from the inlet 640 to the outlet 645 to a closed position that blocks or contacts the valve seat 670 and does not allow the fluid to move from the inlet 640 to the outlet 645. The valve seal 620 can be in the closed position, the open position, and a partially-open position, which is between the closed position and the open position.


The valve seal 620, like the diaphragm 520, is made of an elastomeric material. In one embodiment, the elastomeric material is silicon. However, any material that is stretchy like a rubber band can be used. For example, the elastomeric materials include flexible materials, naturally occurring elastic substances (e.g., natural rubber), and synthetically produced substances (e.g., silicon, butyl rubber, neoprene).


The valve seat 670 provides an opening for the valve seal 620 to close or open. To close the screw valve 600, a command signal (e.g., a telemetric signal) is sent to the screw actuator 605 which drives the screw 615 (and the coupling device or mechanism 610) into the valve seal 620 to press the valve seal 620 onto the valve seat 670. To open the screw valve 600, a command signal is sent to the screw actuator 605 which drives the screw 615 (and the coupling device or mechanism 610) away from the valve seal 620 to decompress or move the valve seal 620 away from the valve seat 670.


The pressure/flow sensor 208 may also be included in or coupled to the screw valve 600. For example, one or both of the flow sensor and/or the pressure sensor can be coupled to the valve seat 670 for determining and adjusting an amount of the fluid flowing between the inlet 640 and the outlet 645.



FIG. 6A illustrates the screw 615 displacing the valve seal 620 onto the valve seat 670 to block the fluid from flowing from the inlet 640 to the outlet 645.



FIG. 6B illustrates the screw 615 moved upward such that the valve seal 620 is not touching the valve seat 670 to allow the fluid to flow from the inlet 640 to the outlet 645 as shown by fluid flow indicators 675. The fluid can also flow in the opposite direction as shown by the fluid flow indicators 675.


The lead screw valve 600 provides many advantages when used for the gastric banding system 100. For example, the screw valve 600 achieves a low leak/leakage rate when closed (e.g., closed/sealed tightly) compared to conventional valves and a high flow rate during adjustment. The screw valve 600 is also easier to manufacture than other implantable devices (such as the dome valve 500).


An additional advantage, is that the screw valve 600 can remain in position (e.g., fully open, partially open, tightly closed) in the presence of very high constant and intermittent pressures present from the inlet 640 and the outlet 645. For example, the screw valve 600 can handle high pressures, such as 30 psi. The screw valve 600 can resist high pressures by being overdriven and by being a normally-still valve.


If the screw 615 is intentionally overdriven, the screw 615 presses tightly against the coupling mechanism 610, which presses tightly against the valve seal 620, which presses tightly against the valve seat 670. The term overdriven means that the screw 615 is driven just beyond the point where the valve seal 620 contacts the valve seat 670. The phrase “just beyond” means a point where force is generated. Even though it's not possible (without damage) to move the valve seal 620 beyond the point that it touches the valve seat 670, it is possible to generate force. For example, forces develop in the motor and forces develop loading up the motor. These forces creating a force balance between the valve seal 620 and the valve seat 670. In one embodiment, “just beyond” is a point where an additional force is required from the motor.


Even though the screw 615 drives the valve seal 620 hard into the valve seat 670, in one embodiment, the valve seal 620 is made of a soft material (e.g., silicon) and the valve seat 670 is made of a hard material (e.g., polished stainless steel) such that the two materials can be pressed together without resulting in substantial damage or marring. This tight seal blocks fluid, including fluid under high pressure. The screw 615 can optionally be reversed to relieve any unwanted excess pressure on the screw 615, the coupling mechanism 610, the valve seal 620, and the valve seat 670.


Another advantage of the screw valve 600 is that the screw 615 can resist the opening and closing in the presence of steady or high pressure, without requiring an additional energy, because the screw valve 600 is a normally still valve (as oppose to normally open or normally closed). Thus, in the absence of a drive command, the screw actuated valve will remain in whichever state it was left, whether that was fully open, partially open, or fully closed.


An additional advantage of the screw valve 600 is the amount of positions available to regulate fluid flow. The screw valve 600 can be fully open, fully closed, or anywhere in between, providing significant flexibility in designing actuation drive characteristics. The fluid flow rate can be adjusted by partially opening the screw valve 600. The screw seal 620 can occupy any position by making precise and incremental adjustments to the screw 615. In one embodiment, the screw valve 600 is used in a closed loop system, where a sensor (e.g., flow sensor, a pressure sensor, etc.) is used to adjust the position of the screw 615 to regulate the fluid flow from the inlet 640 to the outlet 645.



FIGS. 7A, 7B and 7C illustrate side views of examples of the coupling mechanism 610 illustrated in FIG. 6 according to various embodiments of the present invention. FIG. 7A illustrates a tappet 705 as the coupling mechanism 610. The tappet 705 can be a sliding rod for moving a valve. The tappet 705 touches the screw 615, and connects or rides on the screw 615. The tappet 705 allows an intentional rotational slippage between the tappet 705 and the screw 615 to decouple the rotational motion.



FIG. 7B illustrates a ball 710 along with the tappet 705 as the coupling mechanism 610. The ball 710 is located between the screw 615 and the tappet 705. The ball 710 provides two surfaces designed to allow an intentional rotational slippage between the screw 615 and the valve seal 620. Having two surfaces for slippage is advantageous because one surface may bind-up due to particulate contamination (e.g., particles from the screw 615 or the tappet 705) or manufacturing imperfection (e.g., molding flash, burrs, etc.). The ball 710 can be a ball bearing.



FIG. 7C illustrates a bellows unit 715 as the coupling mechanism 610 used with the screw 615. The bellows unit 715 can isolate the screw 615 from the valve seal 620. Without the bellows unit 715, the screw 615 would rotate and rub against a surface of the valve seal 620 generating particulates which are further rubbed against the valve seal 620. Since the valve seal 620 can be sensitive and not designed to be rubbed with particulates, the bellows unit 715 advantageously keeps all the possible generated particulates enclosed and sealed away from the valve seal 620.



FIG. 8 is a flow chart of a method of using the dome valve 500 to control the movement of fluid between the reservoir 104 and the inflatable portion 114 of the gastric band 102.


The process starts at step 800. At step 805, the dome valve 500 receives a telemetric signal from the remote transmitter 108. Alternatively, the dome valve 500 can receive a signal from an implanted microcontroller. The implanted microcontroller may be part of, coupled to or located within the actuator 505. The implanted microcontroller can receive a telemetric signal from the remote transmitter 108. Next, the actuator 505 applies a downward force on the diaphragm 520 to open the dome valve 500 at step 810. The downward force is applied onto the diaphragm edges 525 of the diaphragm 520 in the dome valve 500, lifting up the diaphragm center 527, and allowing fluid to flow through the dome valve 500.


At step 815, the actuator 505 reduces the downward force on the diaphragm 520 to close the dome valve 500. The downward force is reduced on the diaphragm edges 525 of the diaphragm 520 in the dome valve 500, lowering the diaphragm center 527, and blocking fluid from flowing through the dome valve 500. The process ends at step 820.



FIG. 9 is a flow chart of a method of using the screw valve 600 to control the movement of fluid between the reservoir 104 and the inflatable portion 114 of the gastric band 102.


The process starts at step 900. At step 905, the screw valve 600 receives a telemetric signal from the remote transmitter 108. Alternatively, the dome valve 600 can receive a signal from an implanted microcontroller. The implanted microcontroller may be part of, coupled to or located within the screw actuator 605. The implanted microcontroller can receive a telemetric signal from the remote transmitter 108. At step 910, the screw actuator 605 turns the screw 615 in one direction to increase a force on the valve seal 620 to close the screw valve 600.


Then, the screw actuator 605 turns the screw 615 in the opposite direction to decrease the force on the valve seal 620 to open the screw valve 600. The process ends at step 920.


Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.


Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.


The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the present invention.


Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.


Certain embodiments of the present invention are described herein, including the best mode known to the inventors for carrying out the present invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the present invention to be practiced otherwise than specifically described herein. Accordingly, the present invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the present invention unless otherwise indicated herein or otherwise clearly contradicted by context.


Furthermore, references may have been made to patents and printed publications in this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.


Specific embodiments disclosed herein may be further limited in the claims using consisting of or and consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the present invention so claimed are inherently or expressly described and enabled herein.


In closing, it is to be understood that the embodiments of the present invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the present invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims
  • 1. An implantable device for controlling movement of a fluid to an inflatable portion of a gastric band, the implantable device comprising: a body having an inlet, an outlet and a single valve seat positioned between the inlet and the outlet, the valve seat being in fluid communication with the inlet and the outlet, the body defining a fluid passage from the inlet to the outlet;a diaphragm having one or more edges coupled to the body, the diaphragm being made of an elastomeric material, wherein the diaphragm is directly seated on the valve seat in a closed position that blocks the valve seat and blocks fluid communication between the inlet and the outlet, and wherein the diaphragm is not seated on the valve seat in an open position that does not block the valve seat and does not block fluid communication between the inlet and the outlet;an actuator configured to apply a downward force, in a direction from the diaphragm toward the valve seat, on the diaphragm causing the diaphragm to move from the closed position to the open position; anda microcontroller coupled to the actuator, the microcontroller configured to receive a telemetric signal from a remote transmitter and control the actuator based on the telemetric signal.
  • 2. The implantable device of claim 1 further comprising a cap, coupled between the diaphragm and the actuator, for directing the force from the actuator to the diaphragm.
  • 3. The implantable device of claim 1 wherein the force is applied on the one or more edges of the diaphragm.
  • 4. The implantable device of claim 1 wherein the diaphragm prevents the fluid from coming into direct contact with the actuator.
  • 5. The implantable device of claim 1 wherein the diaphragm is made of a flexible material.
  • 6. The implantable device of claim 1 wherein the diaphragm is in the open position when the actuator is in an energized state.
  • 7. The implantable device of claim 1 wherein the diaphragm is in the closed position when the actuator is in an unenergized state.
  • 8. The implantable device of claim 1 wherein the actuator is selected from a group consisting of a solenoid, a stepper motor, a piezoelectric actuator, an electroactive polymer, and combinations thereof.
  • 9. The implantable device of claim 1 wherein the remote transmitter transmits the telemetric signal to the microcontroller.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/712,952, filed Feb. 25, 2010, which is a continuation-in-part of U.S. patent application Ser. No. 12/603,058, filed Oct. 21, 2009, now U.S. Pat. No. 8,366,602, which claims the benefit of U.S. Provisional Patent Application No. 61/107,576, filed Oct. 22, 2008, the entire disclosure of each of these applications are incorporated herein by reference.

US Referenced Citations (639)
Number Name Date Kind
1174814 Brennan Mar 1916 A
1830947 Klingel Nov 1931 A
2013025 Bottoms Apr 1934 A
1999683 Borresen Apr 1935 A
2163048 McKee Jun 1939 A
2339138 Black Jan 1944 A
2405667 Andrew Aug 1946 A
2438231 Schultz Mar 1948 A
2635907 Heimbuch Apr 1953 A
2714469 Carlson Aug 1955 A
2936980 Rapata May 1960 A
3059645 Hasbrouck Oct 1962 A
3189961 Heller Jun 1965 A
3667081 Burger Jun 1972 A
3840018 Heifetz Oct 1974 A
3955834 Ahlrot May 1976 A
4053176 Hilbush Oct 1977 A
4117727 Friswell Oct 1978 A
4118805 Reimels Oct 1978 A
4133315 Berman Jan 1979 A
4157713 Clarey Jun 1979 A
4176412 Peterson Dec 1979 A
4236521 Lauterjung Dec 1980 A
4271827 Angelchik Jun 1981 A
4286584 Sampson Sep 1981 A
4299012 Oetiker Nov 1981 A
4340083 Cummins Jul 1982 A
4370982 Reilly Feb 1983 A
4399809 Baro Aug 1983 A
4406656 Hattler Sep 1983 A
4408597 Tenney Oct 1983 A
4417567 Trick Nov 1983 A
4424208 Wallace Jan 1984 A
4442153 Meltsch Apr 1984 A
4450375 Siegal May 1984 A
4485805 Foster Dec 1984 A
4492004 Oetiker Jan 1985 A
4551862 Haber Nov 1985 A
4558699 Bashour Dec 1985 A
4559699 Owen Dec 1985 A
4582640 Smestad Apr 1986 A
4582865 Balazs Apr 1986 A
4592339 Kuzmak Jun 1986 A
4592355 Antebi Jun 1986 A
4601713 Fuqua Jul 1986 A
4603699 Himpens Aug 1986 A
4667672 Romanoski May 1987 A
4671351 Rappe Jun 1987 A
4693695 Cheng Sep 1987 A
4694827 Weiner Sep 1987 A
4696288 Kuzmak Sep 1987 A
4708140 Baron Nov 1987 A
4716154 Maelson Dec 1987 A
4753086 Schmidt Jun 1988 A
4760837 Petit Aug 1988 A
4803075 Wallace Feb 1989 A
4858619 Toth Aug 1989 A
4872483 Shah Oct 1989 A
4881939 Newman Nov 1989 A
4883467 Franetzki Nov 1989 A
4886787 de Belder et al. Dec 1989 A
4896787 Delamour Jan 1990 A
4915690 Cone Apr 1990 A
4919650 Feingold Apr 1990 A
4925446 Garay May 1990 A
4944487 Holtermann Jul 1990 A
4944659 Labbe Jul 1990 A
4958791 Nakamura Sep 1990 A
4969899 Cox Nov 1990 A
4989756 Kagamihara Feb 1991 A
4994019 Fernandez Feb 1991 A
5045060 Melsky Sep 1991 A
5074868 Kuzmak Dec 1991 A
5084061 Gau Jan 1992 A
5089019 Grandjean Feb 1992 A
5091171 Yu Feb 1992 A
5116652 Alzner May 1992 A
5120313 Elftman Jun 1992 A
5143724 Leshchiner Sep 1992 A
5152770 Bengmark Oct 1992 A
5160338 Vincent Nov 1992 A
5188609 Bayless Feb 1993 A
5224494 Enhorning Jul 1993 A
5226429 Kuzmak Jul 1993 A
5246456 Wilkinson Sep 1993 A
5246698 Leshchiner Sep 1993 A
5259399 Brown Nov 1993 A
5277333 Shimano Jan 1994 A
5318533 Adams Jun 1994 A
5326349 Baraff Jul 1994 A
5343894 Frisch Sep 1994 A
5356883 Kuo Oct 1994 A
5360445 Goldowsky Nov 1994 A
5383858 Reilly Jan 1995 A
5391156 Hildwein Feb 1995 A
5399351 Leshchiner Mar 1995 A
5425716 Kawasaki Jun 1995 A
5449363 Brust Sep 1995 A
5449368 Kuzmak Sep 1995 A
5458568 Racchini Oct 1995 A
5496312 Klicek Mar 1996 A
5496313 Gentelia Mar 1996 A
5509888 Miller Apr 1996 A
5531716 Luzio Jul 1996 A
5535752 Halperin Jul 1996 A
5554113 Novak Sep 1996 A
5562714 Grevious Oct 1996 A
5569839 Ajot Oct 1996 A
5601604 Vincent Feb 1997 A
5607418 Arzbaecher Mar 1997 A
5633001 Angstrom May 1997 A
5649546 Steinbeck Jul 1997 A
5653718 Yoon Aug 1997 A
5658298 Vincent Aug 1997 A
5669416 Nusche Sep 1997 A
5676162 Larson Oct 1997 A
5681284 Herskowitz Oct 1997 A
5695504 Gifford Dec 1997 A
5704893 Timm Jan 1998 A
5713911 Racenet Feb 1998 A
5733257 Sternby Mar 1998 A
5741232 Reilly Apr 1998 A
5748200 Funahashi May 1998 A
5758667 Slettenmark Jun 1998 A
5759015 Van Lintel et al. Jun 1998 A
5766232 Grevious Jun 1998 A
5769877 Barreras Jun 1998 A
5785295 Tsai Jul 1998 A
5795333 Reilly Aug 1998 A
5807311 Palestrant Sep 1998 A
5808203 Nolan Sep 1998 A
5817113 Gifford Oct 1998 A
5827529 Ono Oct 1998 A
5833698 Hinchliffe Nov 1998 A
5861014 Familoni Jan 1999 A
RE36176 Kuzmak Mar 1999 E
5886042 Yu Mar 1999 A
5891089 Katz Apr 1999 A
5904697 Gifford May 1999 A
5910149 Kuzmak Jun 1999 A
5928195 Malamud Jul 1999 A
5938669 Klaiber Aug 1999 A
5944696 Bayless Aug 1999 A
5944751 Laub Aug 1999 A
5993473 Chan Nov 1999 A
5997502 Reilly Dec 1999 A
6010511 Murphy Jan 2000 A
6013679 Kuo Jan 2000 A
6024340 Lazarus Feb 2000 A
6024704 Meador Feb 2000 A
6042345 Bishop Mar 2000 A
6048309 Flom Apr 2000 A
6067991 Forsell May 2000 A
6074341 Anderson Jun 2000 A
6074378 Mouri Jun 2000 A
6083249 Familoni Jul 2000 A
6090064 Reilly Jul 2000 A
6090131 Daley Jul 2000 A
6102678 Peclat Aug 2000 A
6102922 Jakobsson Aug 2000 A
6117086 Shulze Sep 2000 A
6129668 Haynor Oct 2000 A
6164933 Tani Dec 2000 A
6171321 Gifford Jan 2001 B1
6179569 Kojima Jan 2001 B1
6193734 Bolduc Feb 2001 B1
6203523 Haller Mar 2001 B1
6210345 Van Brunt Apr 2001 B1
6210347 Forsell Apr 2001 B1
6221024 Miesel Apr 2001 B1
6224857 Romeo May 2001 B1
6306088 Krausman Oct 2001 B1
6306116 Hancock Oct 2001 B1
6327503 Familoni Dec 2001 B1
6371942 Schwartz Apr 2002 B1
6371965 Gifford Apr 2002 B2
6372494 Naughton Apr 2002 B1
6383218 Sourdile May 2002 B1
6383219 Telandro May 2002 B1
6387105 Gifford May 2002 B1
6402717 Reilly Jun 2002 B1
6402718 Reilly Jun 2002 B1
6417750 Sohn Jul 2002 B1
6418934 Chin Jul 2002 B1
6419696 Ortiz Jul 2002 B1
6432040 Meah Aug 2002 B1
6439539 Powell Aug 2002 B1
6443957 Addis Sep 2002 B1
6443965 Gifford Sep 2002 B1
6450173 Forsell Sep 2002 B1
6450946 Forsell Sep 2002 B1
6450987 Kramer Sep 2002 B1
6451034 Gifford Sep 2002 B1
6453907 Forsell Sep 2002 B1
6454699 Forsell Sep 2002 B1
6454700 Forsell Sep 2002 B1
6454701 Forsell Sep 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6457801 Fish Oct 2002 B1
6460543 Forsell Oct 2002 B1
6461293 Forsell Oct 2002 B1
6463935 Forsell Oct 2002 B1
6464628 Forsell Oct 2002 B1
6470892 Forsell Oct 2002 B1
6474584 Ekich Nov 2002 B2
6475136 Forsell Nov 2002 B1
6475192 Reilly Nov 2002 B1
6485496 Suyker Nov 2002 B1
6491704 Gifford Dec 2002 B2
6491705 Gifford Dec 2002 B2
6511490 Robert Jan 2003 B2
6517556 Monassevitch Feb 2003 B1
6527701 Sayet Mar 2003 B1
6547801 Dargent Apr 2003 B1
6562008 Reilly May 2003 B1
6565582 Gifford May 2003 B2
6579301 Bales Jun 2003 B1
6601604 Cooper Aug 2003 B1
6615084 Cigaina Sep 2003 B1
6630486 Royer Oct 2003 B1
6632239 Snyder Oct 2003 B2
6635020 Tripp Oct 2003 B2
6638258 Schwartz Oct 2003 B2
6646628 Shirochi Nov 2003 B2
6676674 Dudai Jan 2004 B1
6681135 Davis Jan 2004 B1
6685668 Cho Feb 2004 B1
6685963 Taupin Feb 2004 B1
6691047 Fredericks Feb 2004 B1
6715731 Post Apr 2004 B1
6725726 Adolfs Apr 2004 B1
6729600 Mattes May 2004 B2
6733478 Reilly May 2004 B2
6754527 Stroebel Jun 2004 B2
6767924 Yu Jul 2004 B2
6778927 Cha Aug 2004 B2
6799698 Ono Oct 2004 B2
6808513 Reilly Oct 2004 B2
6811136 Eberhardt Nov 2004 B2
6820651 Seuret Nov 2004 B2
6834201 Gillies Dec 2004 B2
6871090 He Mar 2005 B1
6889086 Mass May 2005 B2
6916326 Benchetrit Jul 2005 B2
6921819 Piron Jul 2005 B2
6924273 Pierce Aug 2005 B2
6940467 Fischer Sep 2005 B2
6966875 Longobardi Nov 2005 B1
7017583 Forsell Mar 2006 B2
7017883 Bayer Mar 2006 B2
7021147 Subramanian Apr 2006 B1
7027935 Shimase Apr 2006 B2
7037344 Kagan May 2006 B2
7040349 Moler May 2006 B2
7044933 VanDiver May 2006 B2
7048519 Fong May 2006 B2
7054690 Imran May 2006 B2
7058434 Wang Jun 2006 B2
7060080 Bachmann Jun 2006 B2
7066486 Lee Jun 2006 B2
7118526 Egle Oct 2006 B2
7119062 Alvis Oct 2006 B1
7128750 Stergiopulos Oct 2006 B1
7144400 Byrum Dec 2006 B2
7172607 Hoefle Feb 2007 B2
7177693 Starkebaum Feb 2007 B2
7191007 Desai Mar 2007 B2
7195610 Flachbart Mar 2007 B1
7198250 East Apr 2007 B2
7204821 Clare Apr 2007 B1
7206637 Salo Apr 2007 B2
7223239 Schulze May 2007 B2
7238191 Bachmann Jul 2007 B2
7240607 Fish Jul 2007 B2
7255675 Gertner Aug 2007 B2
7263405 Boveja Aug 2007 B2
7282023 Frering Oct 2007 B2
7284966 Xu Oct 2007 B2
7288064 Boustani Oct 2007 B2
7297103 Jarsaillon Nov 2007 B2
7299082 Feldman Nov 2007 B2
7310557 Maschino Dec 2007 B2
7311503 Van Lintel et al. Dec 2007 B2
7311716 Byrum Dec 2007 B2
7311717 Egle Dec 2007 B2
7314443 Jordan Jan 2008 B2
7314598 Nishino Jan 2008 B2
7314636 Caseres Jan 2008 B2
7338433 Coe Mar 2008 B2
7340306 Barrett Mar 2008 B2
7351198 Byrum Apr 2008 B2
7351240 Hassler Apr 2008 B2
7353747 Swayze Apr 2008 B2
7364542 Jambor Apr 2008 B2
7366571 Armstrong Apr 2008 B2
7367340 Nelson May 2008 B2
7367937 Jambor May 2008 B2
7374565 Hassler May 2008 B2
7390294 Hassler Jun 2008 B2
7396353 Lorenzen Jul 2008 B2
7416528 Crawford Aug 2008 B2
7457668 Cancel Nov 2008 B2
7481763 Hassler Jan 2009 B2
7500944 Byrum Mar 2009 B2
7502649 Ben-Haim Mar 2009 B2
7507221 Neer Mar 2009 B2
7530943 Lechner May 2009 B2
7585280 Wilson Sep 2009 B2
7594885 Byrum Sep 2009 B2
7599743 Hassler Oct 2009 B2
7599744 Giordano Oct 2009 B2
7601162 Hassler Oct 2009 B2
7615001 Jambor Nov 2009 B2
7618365 Jambor Nov 2009 B2
7658196 Ferreri Feb 2010 B2
7670279 Gertner Mar 2010 B2
7699770 Hassler Apr 2010 B2
7712470 Gertner May 2010 B2
7727141 Hassler Jun 2010 B2
7741476 Lebreton Jun 2010 B2
7758493 Gingras Jul 2010 B2
7763039 Ortiz Jul 2010 B2
7766815 Ortiz Aug 2010 B2
7771439 Griffiths Aug 2010 B2
7775215 Hassler Aug 2010 B2
7775966 Dlugos Aug 2010 B2
7775967 Gertner Aug 2010 B2
7794386 Brooks Sep 2010 B2
7811298 Birk Oct 2010 B2
7824422 Benchetrit Nov 2010 B2
7828813 Mouton Nov 2010 B2
7832407 Gertner Nov 2010 B2
7841978 Gertner Nov 2010 B2
7844342 Dlugos Nov 2010 B2
7862502 Pool Jan 2011 B2
7879068 Dlugos Feb 2011 B2
7927270 Dlugos Apr 2011 B2
7951067 Byrum May 2011 B2
20010011543 Forsell Aug 2001 A1
20020038105 Schwartz Mar 2002 A1
20020072780 Foley Jun 2002 A1
20020091395 Gabbay Jul 2002 A1
20020095181 Beyar Jul 2002 A1
20020098097 Singh Jul 2002 A1
20020123716 VanDiver Sep 2002 A1
20020133081 Ackerman Sep 2002 A1
20020139208 Yatskov Oct 2002 A1
20020152816 Kim Oct 2002 A1
20020177811 Reilly Nov 2002 A1
20020183765 Adams Dec 2002 A1
20020193679 Malave Dec 2002 A1
20020198548 Robert Dec 2002 A1
20030009123 Brugger Jan 2003 A1
20030014003 Gertner Jan 2003 A1
20030019498 Forsell Jan 2003 A1
20030045775 Forsell Mar 2003 A1
20030045902 Weadock Mar 2003 A1
20030055311 Neukermans Mar 2003 A1
20030060754 Reilly Mar 2003 A1
20030060873 Gertner Mar 2003 A1
20030066536 Forsell Apr 2003 A1
20030073880 Polsky Apr 2003 A1
20030093157 Casares May 2003 A1
20030100910 Gifford May 2003 A1
20030120288 Benchetrit Jun 2003 A1
20030148995 Piron Aug 2003 A1
20030158564 Benchetrit Aug 2003 A1
20030158569 Wazne Aug 2003 A1
20030167022 Dijkman Sep 2003 A1
20030171887 Cha Sep 2003 A1
20030181890 Schulze Sep 2003 A1
20030181917 Gertner Sep 2003 A1
20030191433 Prentiss Oct 2003 A1
20030208212 Cigaina Nov 2003 A1
20030213285 Wheeler Nov 2003 A1
20040000843 East Jan 2004 A1
20040034479 Shimase Feb 2004 A1
20040044332 Stergiopulos Mar 2004 A1
20040049209 Benchetrit Mar 2004 A1
20040059393 Policker Mar 2004 A1
20040068847 Belisle Apr 2004 A1
20040069714 Ferguson Apr 2004 A1
20040106899 McMichael Jun 2004 A1
20040133219 Forsell Jul 2004 A1
20040147816 Policker Jul 2004 A1
20040148034 Kagan Jul 2004 A1
20040153106 Dudai Aug 2004 A1
20040162595 Foley Aug 2004 A1
20040171942 Ackerman Sep 2004 A1
20040215159 Forsell Oct 2004 A1
20040230137 Mouton Nov 2004 A1
20040235025 Mori Nov 2004 A1
20040243057 Vinten-Johansen Dec 2004 A1
20040254533 Schriver Dec 2004 A1
20040254536 Conlon Dec 2004 A1
20040254537 Conlon Dec 2004 A1
20040260319 Egle Dec 2004 A1
20040267288 Byrum Dec 2004 A1
20040267291 Byrum Dec 2004 A1
20040267292 Byrum Dec 2004 A1
20040267293 Byrum Dec 2004 A1
20040267377 Egle Dec 2004 A1
20050002984 Byrum Jan 2005 A1
20050038484 Knudson Feb 2005 A1
20050038498 Dubrow Feb 2005 A1
20050055039 Burnett Mar 2005 A1
20050070934 Tanaka Mar 2005 A1
20050070937 Jambor Mar 2005 A1
20050082793 Lee Apr 2005 A1
20050100779 Gertner May 2005 A1
20050104457 Jordan May 2005 A1
20050109973 Glime et al. May 2005 A1
20050119672 Benchetrit Jun 2005 A1
20050119674 Gingras Jun 2005 A1
20050131383 Chen Jun 2005 A1
20050131485 Knudson Jun 2005 A1
20050136122 Sadozai Jun 2005 A1
20050142152 Leshchiner Jun 2005 A1
20050143765 Bachmann Jun 2005 A1
20050143766 Bachmann Jun 2005 A1
20050154274 Jarsaillon Jul 2005 A1
20050171568 Duffy Aug 2005 A1
20050177111 Ozeri Aug 2005 A1
20050183730 Byrum Aug 2005 A1
20050192531 Birk Sep 2005 A1
20050192601 Demarais Sep 2005 A1
20050192614 Binmoeller Sep 2005 A1
20050192629 Saadat Sep 2005 A1
20050216042 Gertner Sep 2005 A1
20050226936 Agerup Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050240155 Conlon Oct 2005 A1
20050240156 Conlon Oct 2005 A1
20050240279 Kagan Oct 2005 A1
20050244288 Oneill Nov 2005 A1
20050250979 Coe Nov 2005 A1
20050251181 Bachmann Nov 2005 A1
20050251182 Bachmann Nov 2005 A1
20050267406 Hassler Dec 2005 A1
20050267500 Hassler Dec 2005 A1
20050267533 Gertner Dec 2005 A1
20050271729 Wang Dec 2005 A1
20050277899 Conlon Dec 2005 A1
20050283041 Egle Dec 2005 A1
20050288739 Hassler Dec 2005 A1
20050288740 Hassler Dec 2005 A1
20060009697 Banet Jan 2006 A1
20060015138 Gertner Jan 2006 A1
20060020298 Camilleri Jan 2006 A1
20060041183 Massen Feb 2006 A1
20060074439 Garner Apr 2006 A1
20060074473 Gertner Apr 2006 A1
20060079766 Neer Apr 2006 A1
20060079767 Gibbs Apr 2006 A1
20060089571 Gertner Apr 2006 A1
20060122147 Wohlrab Jun 2006 A1
20060142700 Sobelman Jun 2006 A1
20060142790 Gertner Jun 2006 A1
20060149161 Wilson Jul 2006 A1
20060161139 Levine Jul 2006 A1
20060161186 Hassler Jul 2006 A1
20060167531 Gertner Jul 2006 A1
20060173238 Starkebaum Aug 2006 A1
20060173424 Conlon Aug 2006 A1
20060178555 Bortolotti Aug 2006 A1
20060183967 Lechner Aug 2006 A1
20060189887 Hassler Aug 2006 A1
20060189888 Hassler Aug 2006 A1
20060189889 Gertner Aug 2006 A1
20060194758 Lebreton Aug 2006 A1
20060195139 Gertner Aug 2006 A1
20060197412 Rasmussen Sep 2006 A1
20060199997 Hassler Sep 2006 A1
20060211912 Dlugos Sep 2006 A1
20060211913 Dlugos Sep 2006 A1
20060211914 Hassler Sep 2006 A1
20060212051 Snyder Sep 2006 A1
20060212053 Gertner Sep 2006 A1
20060235448 Roslin Oct 2006 A1
20060246137 Hermitte Nov 2006 A1
20060247721 Maschino Nov 2006 A1
20060247722 Maschino Nov 2006 A1
20060247724 Gerber Nov 2006 A1
20060252982 Hassler Nov 2006 A1
20060252983 Lembo Nov 2006 A1
20060257488 Hubbard Nov 2006 A1
20060264699 Gertner Nov 2006 A1
20060264762 Starr Nov 2006 A1
20060276812 Hill Dec 2006 A1
20060293627 Byrum Dec 2006 A1
20070001447 Fennington Jan 2007 A1
20070015954 Dlugos Jan 2007 A1
20070015955 Tsonton Jan 2007 A1
20070015956 Crawford Jan 2007 A1
20070016231 Jambor Jan 2007 A1
20070016262 Gross Jan 2007 A1
20070027356 Ortiz Feb 2007 A1
20070027358 Gertner Feb 2007 A1
20070044655 Fish Mar 2007 A1
20070077292 Pinsky Apr 2007 A1
20070078476 Hull Apr 2007 A1
20070106153 Neer May 2007 A1
20070125826 Shelton Jun 2007 A1
20070156013 Birk Jul 2007 A1
20070167672 Dlugos Jul 2007 A1
20070167982 Gertner Jul 2007 A1
20070173685 Jambor Jul 2007 A1
20070173888 Gertner Jul 2007 A1
20070179335 Gertner Aug 2007 A1
20070185373 Tsonton Aug 2007 A1
20070185462 Byrum Aug 2007 A1
20070191717 Rosen Aug 2007 A1
20070213836 Paganon Sep 2007 A1
20070218083 Brooks Sep 2007 A1
20070219597 Kamen et al. Sep 2007 A1
20070232848 Forsell Oct 2007 A1
20070232849 Gertner Oct 2007 A1
20070233170 Gertner Oct 2007 A1
20070235083 Dlugos Oct 2007 A1
20070243227 Gertner Oct 2007 A1
20070250085 Bachmann Oct 2007 A1
20070250086 Wiley Oct 2007 A1
20070255335 Herbert Nov 2007 A1
20070255336 Herbert Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070265645 Birk Nov 2007 A1
20070265646 McCoy Nov 2007 A1
20070293716 Baker Dec 2007 A1
20070298005 Thibault Dec 2007 A1
20080009680 Hassler Jan 2008 A1
20080015406 Dlugos Jan 2008 A1
20080015501 Gertner Jan 2008 A1
20080027269 Gertner Jan 2008 A1
20080027469 Bachmann Jan 2008 A1
20080071306 Gertner Mar 2008 A1
20080097496 Chang Apr 2008 A1
20080108862 Jordan May 2008 A1
20080108896 Gibbs May 2008 A1
20080108941 Neer May 2008 A1
20080108943 Wagner May 2008 A1
20080114302 Neer May 2008 A1
20080147002 Gertner Jun 2008 A1
20080161717 Gertner Jul 2008 A1
20080161875 Stone Jul 2008 A1
20080166028 Turek Jul 2008 A1
20080167647 Gertner Jul 2008 A1
20080167648 Gertner Jul 2008 A1
20080172072 Pool Jul 2008 A1
20080188766 Gertner Aug 2008 A1
20080195092 Kim Aug 2008 A1
20080208240 Paz Aug 2008 A1
20080221598 Dlugos Sep 2008 A1
20080243071 Quijano Oct 2008 A1
20080249806 Dlugos Oct 2008 A1
20080250340 Dlugos Oct 2008 A1
20080250341 Dlugos Oct 2008 A1
20080255403 Voegele Oct 2008 A1
20080255414 Voegele Oct 2008 A1
20080255425 Voegele Oct 2008 A1
20080255459 Voegele Oct 2008 A1
20080255537 Voegele Oct 2008 A1
20080275294 Gertner Nov 2008 A1
20080275295 Gertner Nov 2008 A1
20080275484 Gertner Nov 2008 A1
20080281347 Gertner Nov 2008 A1
20080287969 Tsonton Nov 2008 A1
20080287974 Widenhouse Nov 2008 A1
20080287976 Weaner Nov 2008 A1
20080294097 Kim Nov 2008 A1
20080300618 Gertner Dec 2008 A1
20080306443 Neer Dec 2008 A1
20080319435 Rioux Dec 2008 A1
20090054914 Lechner Feb 2009 A1
20090062825 Pool Mar 2009 A1
20090062826 Steffen Mar 2009 A1
20090082793 Birk Mar 2009 A1
20090118572 Lechner May 2009 A1
20090149874 Ortiz Jun 2009 A1
20090157106 Marcotte Jun 2009 A1
20090157107 Kierath Jun 2009 A1
20090157113 Marcotte Jun 2009 A1
20090163803 Neer Jun 2009 A1
20090171375 Coe Jul 2009 A1
20090171378 Coe Jul 2009 A1
20090171379 Coe Jul 2009 A1
20090187202 Ortiz Jul 2009 A1
20090188494 Imai Jul 2009 A1
20090192404 Ortiz Jul 2009 A1
20090192415 Ortiz Jul 2009 A1
20090192533 Dlugos Jul 2009 A1
20090192534 Ortiz Jul 2009 A1
20090192541 Ortiz Jul 2009 A1
20090198261 Schweikert Aug 2009 A1
20090202387 Dlugos Aug 2009 A1
20090204131 Ortiz Aug 2009 A1
20090204132 Ortiz Aug 2009 A1
20090204141 Dlugos Aug 2009 A1
20090204179 Dlugos Aug 2009 A1
20090209995 Byrum Aug 2009 A1
20090216193 Schriver Aug 2009 A1
20090216255 Coe Aug 2009 A1
20090220176 Fusco Sep 2009 A1
20090222031 Axelsson Sep 2009 A1
20090222065 Dlugos Sep 2009 A1
20090228063 Dlugos Sep 2009 A1
20090228072 Coe Sep 2009 A1
20090241677 Klees Oct 2009 A1
20090270759 Wilson Oct 2009 A1
20090270904 Birk Oct 2009 A1
20090306462 Lechner Dec 2009 A1
20090312635 Shimchuk Dec 2009 A1
20090312785 Stone Dec 2009 A1
20100010291 Birk Jan 2010 A1
20100049224 Vargas Feb 2010 A1
20100087843 Bertolote Apr 2010 A1
20100099945 Birk Apr 2010 A1
20100100079 Berkcan Apr 2010 A1
20100145378 Gertner Jun 2010 A1
20100152532 Marcotte Jun 2010 A1
20100168508 Gertner Jul 2010 A1
20100191265 Lau Jul 2010 A1
20100191271 Lau Jul 2010 A1
20100204647 Gertner Aug 2010 A1
20100204723 Gertner Aug 2010 A1
20100217071 Ricol Aug 2010 A1
20100226988 Lebreton Sep 2010 A1
20100228080 Tavori Sep 2010 A1
20100234682 Gertner Sep 2010 A1
20100249803 Griffiths Sep 2010 A1
20100280310 Raven Nov 2010 A1
20100305397 Birk Dec 2010 A1
20100312046 Lau Dec 2010 A1
20100312147 Gertner Dec 2010 A1
20100324358 Birk Dec 2010 A1
20100324359 Birk Dec 2010 A1
20110130626 Hassler Jun 2011 A1
20110201874 Birk Aug 2011 A1
20130253262 Birk Sep 2013 A1
Foreign Referenced Citations (136)
Number Date Country
949965 Jun 1974 CA
1250382 Apr 2000 CN
1367670 Sep 2002 CN
4225524 Feb 1994 DE
19802615 Aug 1999 DE
10020688 Dec 2000 DE
0119596 Sep 1984 EP
0230747 Aug 1987 EP
0416250 Mar 1991 EP
0611561 Aug 1994 EP
0695558 Feb 1996 EP
0876808 Nov 1998 EP
1036545 Sep 2000 EP
1072282 Jan 2001 EP
1105073 Jun 2001 EP
1396242 Mar 2004 EP
1396243 Mar 2004 EP
1491167 Dec 2004 EP
1491168 Dec 2004 EP
1529502 May 2005 EP
1547549 Jun 2005 EP
1574189 Sep 2005 EP
1600183 Nov 2005 EP
1602346 Dec 2005 EP
1704833 Sep 2006 EP
1719480 Nov 2006 EP
1754890 Nov 2006 EP
1736123 Dec 2006 EP
1736195 Dec 2006 EP
1736202 Dec 2006 EP
1743605 Jan 2007 EP
1829504 Sep 2007 EP
1829505 Sep 2007 EP
1829506 Sep 2007 EP
1949875 Jul 2008 EP
1967168 Sep 2008 EP
1922316 Nov 2008 EP
1992315 Nov 2008 EP
1992316 Nov 2008 EP
2074970 Jul 2009 EP
2074971 Jul 2009 EP
2074972 Jul 2009 EP
2087862 Aug 2009 EP
2095796 Sep 2009 EP
2095797 Sep 2009 EP
2095798 Sep 2009 EP
2191796 Jun 2010 EP
1566202 May 1969 FR
2688693 Sep 1993 FR
2769491 Apr 1999 FR
2783153 Mar 2000 FR
2797181 Feb 2001 FR
2799118 Apr 2001 FR
2823663 Oct 2002 FR
2855744 Dec 2004 FR
2921822 Apr 2009 FR
1174814 Dec 1969 GB
2090747 Jul 1982 GB
57171676 Oct 1982 JP
167309 Apr 1989 JP
2019147 Jan 1990 JP
2132104 Nov 1990 JP
3105702 Nov 1991 JP
11244395 Sep 1999 JP
2003526410 Sep 2003 JP
2005131380 May 2005 JP
2005334658 Dec 2005 JP
8503144 Dec 1986 SE
8600079 Jan 1986 WO
8600912 Feb 1986 WO
8911701 Nov 1989 WO
9000369 Jan 1990 WO
9220349 Nov 1992 WO
9402517 Feb 1994 WO
9633751 Jan 1996 WO
9835639 Aug 1998 WO
9835640 Aug 1998 WO
0000108 Jan 2000 WO
0001428 Jan 2000 WO
0009047 Feb 2000 WO
0009048 Feb 2000 WO
0009049 Feb 2000 WO
0015158 Mar 2000 WO
0066196 Nov 2000 WO
0110359 Feb 2001 WO
0112078 Feb 2001 WO
0141671 Jun 2001 WO
0147435 Jul 2001 WO
0147575 Jul 2001 WO
0149245 Jul 2001 WO
0152777 Jul 2001 WO
0168007 Sep 2001 WO
0170131 Sep 2001 WO
0185071 Nov 2001 WO
0205753 Jan 2002 WO
0209792 Feb 2002 WO
0219953 Mar 2002 WO
0226317 Apr 2002 WO
02053093 Jul 2002 WO
02065948 Aug 2002 WO
02096326 Dec 2002 WO
03007782 Jan 2003 WO
03055420 Jul 2003 WO
03057092 Jul 2003 WO
03059215 Jul 2003 WO
03077191 Sep 2003 WO
03101352 Dec 2003 WO
03105732 Dec 2003 WO
2004014245 Feb 2004 WO
2004019671 Mar 2004 WO
2004108025 Dec 2004 WO
2004112563 Dec 2004 WO
2005007232 Jan 2005 WO
2005009305 Feb 2005 WO
2005067994 Jul 2005 WO
2005072195 Aug 2005 WO
2005087147 Sep 2005 WO
2005094447 Oct 2005 WO
2005112888 Dec 2005 WO
2006040647 Apr 2006 WO
2006049725 May 2006 WO
2006083885 Aug 2006 WO
2006108203 Oct 2006 WO
2007067206 Jun 2007 WO
2007081304 Jul 2007 WO
2007106727 Sep 2007 WO
2007114905 Oct 2007 WO
2007145638 Dec 2007 WO
2008063673 May 2008 WO
2008109300 Sep 2008 WO
2008134755 Nov 2008 WO
2009023247 Feb 2009 WO
2009050709 Apr 2009 WO
2009132127 Oct 2009 WO
2009136126 Nov 2009 WO
2010042493 Apr 2010 WO
Non-Patent Literature Citations (91)
Entry
‘Innovative medical devices and implants’; LGSP medical futures, p. 5.
Acuna-Goycolea et al.; ‘Mechanism of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Acruate Nucleus’; The Journal of Neuroscience; V. 25(32); pp. 7406-7419; Aug. 10, 2005.
Adrian et al.; ‘Mechanism of Pancreatic Polypeptide Release in Man.’ The Lancet; pp. 161-163; Jan. 22, 1977.
Anson; ‘Shape Memory Alloys—Medical Applications,’ Source: Materials World, vol. 7, No. 12, pp. 745-747, Dec. 1999.
Asakawa et al; ‘Antagonism of Ghrelin Receptor Reduces Food Intake and Body Weight Gain in Mice’; Gut.; V.52; pp. 947-952; 2003.
Baggio et al. ‘Biology of Integrins: GLP-1 and GIP’; Gastroenrology; V. 132; pp. 2131-2157; 2007.
Ballantyne; ‘Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release, and Actions’; Obesity Surgery; V.16; pp. 651-658; 2006.
Ballantyne; “Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery”; Obesity Surgery; V.16; pp. 795-803; 2006.
Berne et al; ‘Physiology’; V. 5; pp. 55-57, 210, 428, 540, 554, 579, 584, 591; 2004.
BioEnterics Corporation, an Inamed Company, BioEnterics Intragastric Balloon; Directions for Use Published Document, P/N 94200 Rev: B, pp. 1-56.
Bio Enterics Lap-Band Adjustable Gastric Banding System, Inamed Health, pub. Aug. 28, 2003, pp. 1-115.
Boulant et al.; ‘Cholecystokinin in Transient Lower Oesophageal Sphincter Relation Due to Gastric Distension in Humans’; Gut; V. 40; pp. 575-581; 1997.
Bradjewin et al; ‘Dose Ranging Study of the Effects of Cholecystokinin in Healthy Volunteers’; J. Psychiatr. Neurosci.; V. 16 (2); pp. 91-95; 1991.
Burdyga et al.; ‘Cholecystokinin Regulates Expression of Y2 Receptors in Vagal Afferent Neurons Serving the Stomach’; The Journal of Neuroscience; V. 28; No. 45; pp. 11583-11592; Nov. 5, 2008.
Chaptini et al.; “Neuroendocrine Regulation of Food Intake”; Current Opinion in Gastroenterology; V. 24; pp. 223-229; 2008.
Chaudhri; ‘Can Gut Hormones Control Appetite and Prevent Obesity?’ Diabetes Care; V. 31; Supp 2; pp. S284-S289; Feb. 2008.
Cohen et al.; ‘Oxyntomodulin Suppresses Appetite and Reduces Food in Humans’; J. Clin. Endocrinol. Metab.; V. 88; pp. 4696-4701; 2003.
Corno et al.; ‘A new implantable device for telemetric control of pulmonary blood flow’; New ideas; received Apr. 24, 2004; received in revised form Jul. 12, 2002; 10 pages.
Corno et al.; ‘FlowWatchTM in clipped and inclipped position’; Interact Cardio Vase Thorac Surg 2002; 1:46-49; Copyright@2002 The European Asociation for Cardio-thoracic Surgery; 1 page.
Cummings et al.; ‘Plasma Ghrelin Levels After Diet-Induced Weight Loss or Gastric Bypass Surgery’; N. Engl J. Med; V. 346, No. 21; pp. 1623-1630; May 23, 2002.
Cummings; ‘Gastrointestinal Regulation of Foot Intake’; The Food Journal of Clinical Investigation; V. 117, N. 1; pp. 13-23; Jan. 2007.
Dakin et al.; ‘Oxyntomodulin Inhibits Food Intake in the Rat’; Endocrinology; V. 142; pp. 4244-4250; 2001.
Dakin et al.; ‘Peripheral Oxyntomodulin Reduces Food Intake and Body Weight gain in Rats’; Endocrinology; V. 145; No. 6; pp. 2687-2695; Jun. 2004.
Davison; ‘Activation of Vagal-Gastric Mechanoreceptors by Cholecystokinin’; Proc. West. Pharmocol. Soc; V. 29; pp. 363-366; 1986.
De Waele et al.; “Endoscopic Volume Adjustment of Intragastric Balloons for Intolerance”; Obesity Surgery; V. 11; pp. 223-224; 2001.
De Waele et al.; “Intragastric Balloons for Preoperative Weight Reduction”; Obesity Surgery; V. 58; pp. 58-60; 2001.
Desai et al.; ‘Molecular Weight of Heparin Using 13C Nuclear Magnetic Resonance Spectroscopy’ Journal of Pharmaceutical Science, V. 84,12; 1995, Abstract only.
Doldi et al.; ‘Intragastric Balloon: Another Option for Treatment of Obesity and Morbid Obesity’; Hepato-Gastroenterology; V. 51, N. 55; pp. 294-307; Jan.-Feb. 2004.
Doldi et al.; ‘Treatment of Morbid Obesity with Intragastric Balloon in Association with Diet’; Obesity Surgery; V. 10, pp. 583-587; 2000.
Ekblad et al.; ‘Distribution of Pancreatic Peptide and Peptide-YY’; Peptides; V. 23; pp. 251-261;2002.
El Khoury et al.; “Variation in Postprandial Ghrelin Status Following Ingestion of High-Carbohydrate, High Fat, and High Protein Meals in Males”; Ann Nutr Metab; V. 50; pp. 260-269; 2006.
Galloro et al; “Preliminary Endoscopic Technical Report of an New Silicone Intragastric Balloon in the Treatment of Morbid Obesity”; Obesity Surgery; V. 9, pp. 68-71; 1999.
GinShiCel MH Hydroxy Propyl Methyl Cellulose, Web Page http://www.ginshicel.cn/MHPC.html, Nov. 12, 2008.
Girard; ‘The Incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: IncretinsIncretinsIncretinsIncretinsIncretins: Concept and physiological functions’; Diabetes and Metabolism; V. 34; pp. 550-559; 2008.
Greenough et al.; ‘Untangling the Effects of Hunger, Anxiety and Nausea on Energy Intake During Intravenous Cholecystokinin Octapeptide (CCK-8) Infusion’ Physiology and Behavior; V. 65 (2); pp. 303-310; 1998.
Grise et al.; “Peptide YY Inhibits Growth of Human Breast Cancer in Vitro and in Vivo”; Journal of Surgical Research; V. 82; pp. 151-155; 1999.
Grundy; “Signaling the State of the Digestive Tract”; Autonomic Neuroscience: Basic and Clinical; V. 125; pp. 76-80; 2006.
Grundy; “Vagal Control of Gastrointestinal Function”; Bailliere's Clinical Gastroenterology; V. 2; No. 1; pp. 23-43; 1988.
Hallden et al. “Evidence for a Role of the Gut Hormone PYY in the Regulation of Intestinal Fatty Acid Binding Protein Transcripts in Differentiated Subpopulations of Intestinal Epithelial Cell Hybrids”; Journal of Biological Chemistry; V. 272 (19); pp. 125916-126000; 1997.
Hameed et al., ‘Gut Hormones and Appetite Control’, Oral Diseases, 2009, 15:18-26.
Hassan et al.; ‘Effects of Adjuvants to Local Anesthetics on Their Duration III Experimental Studies of Hyaluronic Acid’ Abstract Pub Med [Acta Anesthesiol Scand.; 29 (4): 384-8], 1 page; May 1985.
Hodson et al.; ‘Management of Obesity with the New Intragastric Balloon’; Obesity Surgery; V. 11, pp. 327-329,2001.
Holzer; “Gastrointestinal Afferents as Targets of Novel Drugs for the Treatment of Functional Bowel Disorders and Visceral Pain”; European Journal of Pharmacology; V. 429; pp. 177-193; 2001.
Houpt; ‘Gastrointestinal Factors in Hunger and Satiety’; Neurosci. and Behav. Rev.; V. 6; pp. 145-164; 1982.
Iverson et al.; ‘Recent Advances in Microscale Pumping Technologies: A Review and Evaluation’; Microfluid Nanofluid; vol. 5; pp. 145-174; Feb. 19, 2008.
Jones; “Molecular, pharmacological, and clinical aspects of liraglutide, a oncedaily human GLP-1 analogue”; Molecular and Cellular Endocrinology; V. 297; pp. 137-140; 2009.
Kerem et al.; ‘Exogenous Ghrelin Enhances Endocrine and Exocrine Regeneration in Pancreatectomized Rats’; J. Gastrointest Surg.; V. 13; pp. 775-783, 2009.
Kesty et al., ‘Hormone-based Therapies in the Regulation of Fuel Metabolism and Body Weight’, Expert Opin. Biol. Ther., 2008, 8(11): 1733-1747.
Kissileff et al.; ‘Peptides that Regulate Food Intake: Cholecystokinin and Stomach Distension Combine to Reduce Food Intake in Humans’; Am. J. Physiol. Regul. Integr. Comp. Physiol.; V. 285; pp. 992-998; 2003.
Kojima et al., ‘A Role for Pancreatic Polypeptide in Feeding and Body Weight Regulation’, Peptides, 2007, 28:459-463.
Kulicke et al. “Visco-Elastic Propeerties of Sodium Hyaluronate Solutions,” American Institute of Physics; pp. 585-587; 2008.
Lap-Band AP System Adjustable Gastric Banding System With OmniformTM Design: Directions for Use (DFU); Allergan, 16 pages; 2009.
Le Roux et al.; ‘Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters’; Ann. Surg; V. 243; No. 1; pp. 108-114; Jan. 2006.
Liu et al.; ‘Adjuvant Hormonal Treatment With Peptide YY or Its Analog Decreases Human Pancreatic Carcinoma Growth’; The American Journal of Surgery; V. 171; pp. 192-196; Jan. 1996.
Mathus-Vliegen et al. ‘Intragastric Balloons for Morbid Obesity: Results, Patient Tolerance and Balloon Life Span’; Br. J. Surg.; V. 77, No. 7, pp. 76-79; Jan. 1990.
Mathus-Vliegen et al. “Treating Morbid and Supermorbid Obesity” International Journal of Gastroenterology; V. 5, No. 1, pp. 9-12; 2000.
Medeiros et al.; ‘Processing and metabolism of Peptide-YY: Pivotal roles of Dipeptidase-IV, Aminopeptidase-P, and Endopeptidase-24.11’; Endocrinology; V. 134, No. 5; pp. 2088-2094;1994.
Naslund et al.; ‘Prandial Subcutaneous Injection of Glucagon-Like Peptide’; Br. J. Nutr.; V. 91; pp. 439-446; 2004.
Potier et al.; “Protein, amino acids, and the control of food intake”; Current Opinion in Clinical Nutrition and Metabolic Care; V. 12; pp. 54-58; 2009.
Qjan et al.; ‘Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117’; International Journal of Pharmaceutics; V. 366; pp. 218-220; 2008.
Rang et al.; ‘Pharmacology’; V. 5; pp. 203, 397, 402, 524; 2004.
Raybould et al.; “Integration of Postprandial Gastrointestinal Tract: Role of CCK and Sensory Pathways”; Annals of New York Academy of Science; pp. 143-156; 1994.
Renshaw et al. ‘Peptide YY: A Potential Therapy for Obesity’; Current Drug Targets; V. 6; pp. 171-179; 2005.
Sannino et al., ‘Crosslinking of Cellulose Derivatives and Hyaluronic Acid with Water-Soluble Carbodiimide,’ Polymer 46(2005)pp. 11206-11212.
Shechter et al.; “Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice”; FEBS Letters; V. 579; pp. 2439-2444; 2005.
Silver et al.; ‘Physical Properties of Hyaluronic Acid and Hydroxypropylmethylcellulose in Solution: Evaluation of Coating Ability’ Journal of Applied Biomaterials, V. 5; pp. 89-98, 1994.
Small et al.; ‘Gut hormones and the control of appetite’; Trends in Endocrinology and Metabolism; V. 15; No. 6; pp. 259-263; Aug. 2004.
Stanley et al.; ‘Gastrointestinal Satiety Signals III. Glucagon-like Peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide’; Am. J. Physiol Gastrointest Liver Physiol; V. 286; pp. 693-697; 2004.
Tezel,‘The Science of Hyaluronic Acid Dermal Fillers,’ Journal of Cosmetic and Laser Therapy (2008) 10: pp. 35-42.
Tolhurst et al.; ‘Nutritional regulation of glucagon-like peptidel secretion’; J. Physiol.; V. 587, No. I;pp. 27-32; 2009.
Totte et al.; “Weight Reduction by Means of Intragastric Device: Experience with the Bioenterics Intragastric Balloon”; Obesity Surgery; V. 11, pp. 519-523; 2001.
Tough et al.; ‘Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa’; The Journal of Pharmacology and Experimental Therapeutics; V. 319, No. 1; pp. 20-30; 2006.
Tseng et al; “Peptide YY and cancer: Current findings and potential clinical applications”; Peptides; V. 23; pp. 389-395; 2002.
Valassi et al.; “Neuroendocrine control of food intake”; Nut. Metab. & Cariovasc. Disease; V. 18; pp. 158-168; 2008.
Van Der Lely et al.; “Biological, Physiological, Pathophysiological Aspects of Ghrelin”; Endocrine Reviews; V. 25, No. 3; pp. 426-457; 2004.
Verdich et al. ‘A Meta-Analysis of the Effect of Glucagon-Like-Peptide-1 (7-36) Amide on ad Libitum Energy Intake in Humans’; J. Clin. Endocrinal. Metab. V. 86; pp. 4382-4389; Sep. 2001.
Wahlen et al.; ‘The BioEnterics Intragastric Balloon (BIB): How to Use It’; Obesity Surgery; V. 11; pp. 524-527; 2001.
Wang et al.; “Plasma Ghrelin Modulation in Gastric Band Operation and Sleeve Gastrectomy”; Obes. Surg.; pp. 357-362; 2008.
Weiner et al.; ‘Preparation of Extremely Obese Patients for Laparoscopic Gastric Banding by Gastric Balloon Therapy’; Obesity Surgery; V. 9, pp. 261-264, 1999.
Wynne et al.; ‘Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subiects: A Double-Blind Randomized, Controlled Trial’: Diabetes; V. 54; pp. 2390-2395; 2005.
Yuzuriha et al.; “Gastrointestinal Hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development”; FASEB J.; V. 21; pp. 2108-2112; 2007.
Brown et al; ‘Symmetrical Pouch Dilation After Laparoscopic Adjustable Gastric Banding: Incidence and Management’; Obesity Surgery; V. 18, pp. 1104-1108; 2008.
Ceelen et al.; ‘Surgical Treatment of Severe Obesity With a Low-Pressure Adjustable Gastric Band: Experimental Data and Clinical Results in 625 Patients’; Annals of Surgery; V. 237, No. I;pp. 10-16; 2003.
Dixon et al.; ‘Pregnancy After Lap-Band Surgery: Management of the Band to Achieve Healthy Weight Outcomes’; Obesity Surgery; V. 11, pp. 59-65; 2001.
Helioscopie Product Insert for Heliogast, pp. 1-11 (undated).
Neary et al.; ‘Peptide YY(3-36) and Glucagon-Like Peptide-1.sub.(7-36) Inhibit Food Intake Additively’; Endocrinology; V.146; pp. 5120-5127; 2005.
Padidela et al.; ‘Elevated basal and post-feed glucagon-like petide 1 (GLP-1) concentrations in the neonatel period’; European Journal of Endocrinology; v. 160; pp. 53-58; 2009.
Patient Management After Lap-Band Placement; http://www.core.monash.org/ patient-care.pdf.
Shi et al; ‘Sexually Dimorphic Responses to Fat Loss After Caloric Restriction or Surgical Lipectomy’; Am. J. Physiol. Endocrinol. Metab.; V. 293; E316-E326; 2007.
The Lap-Band Device & How it Works; http://lapband.com/en/learn—about-lapband/device—how—it—works/.
Xanthakos et al.; ‘Bariatric Surgery for Extreme Adolescent Obesity: Indications, Outcomes, and Physiologic Effects on the Gut-Brain Axis’; Pathophysiology; V. 15; pp. 135-146; 2008.
Related Publications (1)
Number Date Country
20130253262 A1 Sep 2013 US
Provisional Applications (1)
Number Date Country
61107576 Oct 2008 US
Continuations (1)
Number Date Country
Parent 12712952 Feb 2010 US
Child 13894955 US
Continuation in Parts (1)
Number Date Country
Parent 12603058 Oct 2009 US
Child 12712952 US